Does an economic incentive affect provider behavior? Evidence from a field experiment on different payment mechanisms.

Abstract:

AIMS:This study analyzed discrepancies in the quantity of medical services supplied by physicians under different payment systems for patients with different health statuses and illnesses by means of a field experiment. METHODS:Based on the laboratory experiment of Heike Hennig-Schmidt, we designed a field experiment to examine fee-for-service (FFS), capitation (CAP), and diagnosis-related group (DRG) payment systems. Medical students were replaced with 220 physicians as experimental subjects, which more closely reflected the clinical choices made by physicians in the real world. Under the three payment mechanisms, the quantity of medical services provided by physicians when they treated patients with different health statuses and illnesses were collected. Finally, relevant statistics were computed and analyzed. RESULTS:It was found that payment systems (sig. = 0.000) and patient health status (sig. = 0.000) had a stronger effect on physicians' choices regarding quantity of medical services than illness types (sig. = 0.793). Additionally, under the FFS and CAP payment systems, physicians overserved patients in good and intermediate health while underserving patients in bad health. Under the DRG payment system, physicians overserved patients in good health and underserved patients in intermediate and bad health. Correspondingly, under FFS and CAP, the proportional loss of benefits was the highest for patients in bad health and the lowest for patients in good and intermediate health; while under DRGs, patients in good and intermediate health had the largest and smallest loss of benefits, respectively. LIMITATIONS:In order to increase external effects of experiment results, we used the field experiment to replace laboratory experiment. However, the external effects still existed because of the blurring and abstraction of the parameters. CONCLUSIONS:Medical treatment cost and price affected the quantity of medical services provided by physicians. Therefore, we proposed that a mix of payment systems could address the common interests of physicians and patients, as well as influence incentives from payment systems.

journal_name

J Med Econ

authors

Xi X,Wang E,Lu Q,Chen P,Wo T,Tang K

doi

10.1080/13696998.2018.1539399

subject

Has Abstract

pub_date

2019-01-01 00:00:00

pages

35-44

issue

1

eissn

1369-6998

issn

1941-837X

journal_volume

22

pub_type

杂志文章
  • Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.

    abstract:OBJECTIVE:This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS:A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1571500

    authors: Wu JJ,Pelletier C,Ung B,Tian M

    更新日期:2019-04-01 00:00:00

  • Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise.

    abstract:OBJECTIVE:The spectrum of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) represents a large burden on healthcare systems around the world. Meningitis, bacteraemia, community-acquired pneumonia (CAP), and acute otitis media (AOM) are vaccine-preventable infectious diseases tha...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2011.622323

    authors: Knerer G,Ismaila A,Pearce D

    更新日期:2012-01-01 00:00:00

  • Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.

    abstract:OBJECTIVE:To assess patient characteristics, treatment patterns, and healthcare resource utilization (HRU)/costs of individuals treated for neuroendocrine tumors (NETs) in the US. METHODS:Using a US administrative claims database, this study identified commercially-insured adults newly diagnosed with carcinoid tumors ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.975233

    authors: Chuang CC,Bhurke S,Chen SY,Brulais S,Gabriel S

    更新日期:2015-02-01 00:00:00

  • The economic burden of depression among adults with rheumatoid arthritis in the United States.

    abstract:AIMS:Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to asse...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1572015

    authors: Li N,Chan E,Peterson S

    更新日期:2019-04-01 00:00:00

  • Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database.

    abstract:OBJECTIVE:Systemic lupus erythematosus is a complex autoimmune disease, most frequently affecting women of childbearing age. Women with lupus are at increased risk of pregnancy complications that are exacerbated by active disease. Despite this, their use of medications and hospital resources has not been extensively st...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1066796

    authors: Petri M,Daly RP,Pushparajah DS

    更新日期:2015-01-01 00:00:00

  • Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis.

    abstract:OBJECTIVE:Ulipristal acetate has been found to be non-inferior to other pre-operative treatments of uterine fibroids, particularly leuprolide. The objective of this study was to assess the pharmacoeconomic profile of ulipristal acetate compared to leuprolide for the pre-operative treatment of moderate-to-severe uterine...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1254090

    authors: Zakiyah N,van Asselt AD,Postma MJ

    更新日期:2017-03-01 00:00:00

  • Cost effectiveness of palivizumab in children with congenital heart disease in Germany.

    abstract:OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990903347172

    authors: Nuijten M,Lebmeier M,Wittenberg W

    更新日期:2009-01-01 00:00:00

  • Societal costs of multiple sclerosis in Ireland.

    abstract:AIMS:This paper evaluates the impact of multiple sclerosis (MS) in Ireland, and estimates the associated direct, indirect, and intangible costs to society based on a large nationally representative sample. MATERIALS AND METHODS:A questionnaire was developed to capture the demographics, disease characteristics, healthc...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1427100

    authors: Carney P,O'Boyle D,Larkin A,McGuigan C,O'Rourke K

    更新日期:2018-05-01 00:00:00

  • Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada.

    abstract:BACKGROUND:Approximately 20-30% of Canadians suffer from chronic pain. Guidelines for the management of chronic pain support the use of controlled-release (CR) opioids to treat chronic pain. Although effective in managing chronic pain, oxycodone is associated with high rates of opioid-induced constipation (OIC). The co...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1116992

    authors: Goeree R,Goeree J

    更新日期:2016-01-01 00:00:00

  • The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.

    abstract:INTRODUCTION:The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1580200

    authors: Seetasith A,Wong W,Tse J,Burudpakdee C

    更新日期:2019-05-01 00:00:00

  • Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis.

    abstract:OBJECTIVES:This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. METHODS:Data were extracted from the Spanish Ministry of Health records via a claims database containing patient records from 192 private and ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1840180

    authors: Marsà A,Ascanio M,Diaz-García J,Darbà J

    更新日期:2020-11-02 00:00:00

  • The effects of global budget on cost control and readmission in rural China: a difference-in-difference analysis.

    abstract:BACKGROUND:Global budget (GB) is considered one of the most important payment methods available. Since a new round of healthcare system reforms in 2009, the Chinese government has been paying attention to this prospective payment. However, it is unclear whether GB has influenced cost control and how it works in rural C...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1336448

    authors: He R,Miao Y,Ye T,Zhang Y,Tang W,Li Z,Zhang L

    更新日期:2017-09-01 00:00:00

  • Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings.

    abstract::Objectives: To describe the clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer (mCRPC) in Chinese patients. Methods: This retrospective study identified a group of patients with newly-developed mCRPC from 2012 to 2016 to extract information fr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1600524

    authors: Qian Z,Wang Y,Tang Z,Ren D,Wang Z,Chen W,Li Z

    更新日期:2019-08-01 00:00:00

  • Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting.

    abstract::Aims: This article aimed to examine the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF), from a public healthcare payer's perspective.Materials and methods: Baseline event risks were obtained from the J-ROCKET AF trial ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1688821

    authors: Hori M,Tanahashi N,Akiyama S,Kiyabu G,Dorey J,Goto R

    更新日期:2020-03-01 00:00:00

  • Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.

    abstract:OBJECTIVE:To evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare costs among chronic constipation (CC) patients and estimate incremental all-cause healthcare costs of CC patients relative to matched controls. METHODS:Patients aged ≥18 years with continuous medical and pharmacy ben...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.860375

    authors: Cai Q,Buono JL,Spalding WM,Sarocco P,Tan H,Stephenson JJ,Carson RT,Doshi JA

    更新日期:2014-02-01 00:00:00

  • Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.

    abstract:BACKGROUND:Growing financial pressure on US dialysis providers requires economic efficiency considerations. The objective of this study was to examine short-term economic efficiencies of a cinacalcet-based treatment approach for secondary hyperparathyroidism. METHODS:This study retrospectively assessed cost per bioche...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.3111/13696998.2013.826665

    authors: Belozeroff V,Lee A,Tseng S,Chiroli S,Campbell JD

    更新日期:2013-09-01 00:00:00

  • Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.

    abstract::Aims: Allopurinol is the most common urate lowering therapy (ULT) used to treat gout but may cause life-threatening severe cutaneous adverse reactions (SCAR) in a small number of patients. Risk of SCAR is increased for patients with the HLA-B*58:01 genotype. When alternative ULT is required, febuxostat or probenecid a...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1757456

    authors: Pruis SL,Jeon YK,Pearce F,Thong BY,Aziz MIA

    更新日期:2020-08-01 00:00:00

  • The cost to managed care of managing pulmonary hypertension.

    abstract:OBJECTIVE:To estimate direct medical costs and resource use for commercially-insured patients within two pulmonary hypertension sub-groups: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). RESEARCH DESIGN AND METHODS:Using a retrospective cohort design, subjects (≥18 yea...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.665109

    authors: Said Q,Martin BC,Joish VN,Kreilick C,Mathai SC

    更新日期:2012-01-01 00:00:00

  • A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.

    abstract:AIM:The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes over a 36-month period in patients with type 2 diabetes initiated on NPH or long-acting insulin analogs. METHODS:Electronic patient data from 479 general practices in the UK (THIN database) were examined for new users of ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.991788

    authors: Idris I,Gordon J,Tilling C,Vora J

    更新日期:2015-04-01 00:00:00

  • Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures.

    abstract:OBJECTIVE:The use of hemostatic agents has increased over time for all surgical procedures. The purpose of this study was to evaluate the newer topical absorbable hemostat products Surgicel * Fibrillar † and Surgicel SNoW ‡ (Surgicel advanced products, abbreviated as SAPs) compared to the older product Surgicel Origina...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1017503

    authors: Martyn D,Kocharian R,Lim S,Meckley LM,Miyasato G,Prifti K,Rao Y,Riebman JB,Scaife JG,Soneji Y,Corral M

    更新日期:2015-06-01 00:00:00

  • Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

    abstract:OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.673525

    authors: Langkilde LK,Bergholdt Asmussen M,Overgaard M

    更新日期:2012-01-01 00:00:00

  • Long-term health-related burden of adult congenital heart diseases in Hong Kong.

    abstract::Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1613239

    authors: Lee VWY,Yan BP,Fong TMC,Fung AKP,Cheng FWT

    更新日期:2019-08-01 00:00:00

  • A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.

    abstract:OBJECTIVES:To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective. METHODS:A 5-year Markov cohort model was developed. Costs were obtained from the literature and utiliti...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990903562861

    authors: Brereton N,Bodger K,Kamm MA,Hodgkins P,Yan S,Akehurst R

    更新日期:2010-03-01 00:00:00

  • Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.

    abstract:BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.761633

    authors: Papadopoulos G,Hunt S,Prasad M

    更新日期:2013-01-01 00:00:00

  • Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.

    abstract:AIM:Prescription drug prices in the United States are considered rather extreme. Americans spend over $460 billion on drugs annually, or almost 17 percent of total national healthcare spending. How innovation incentives and insurance coverage drive pricing, diffusion, and utilization of drugs, under conditions of risk ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1772797

    authors: Mendoza RL

    更新日期:2020-09-01 00:00:00

  • Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers.

    abstract:OBJECTIVE:The purpose of this study was to determine the cost effectiveness (from a payer's perspective) of adding clostridial collagenase ointment (CCO) to selective debridement compared with selective debridement alone (non-CCO) in the treatment of stage IV pressure ulcers among patients identified from the US Wound ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1252381

    authors: Carter MJ,Gilligan AM,Waycaster CR,Schaum K,Fife CE

    更新日期:2017-03-01 00:00:00

  • Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.

    abstract:INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1032974

    authors: McGuire A,Martin M,Lenz C,Sollano JA

    更新日期:2015-01-01 00:00:00

  • Budget impact model of a 5-grass sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis.

    abstract:OBJECTIVE:Allergic rhinitis (AR) is a chronic disease with a substantial clinical and economic burden. This study estimated the potential budget impact (BI) associated with market entry of Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use ('5...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1061533

    authors: Ivanova JI,Kelkar S,King S,Birnbaum HG,Hocker S,Phipps R,Lankow R

    更新日期:2015-01-01 00:00:00

  • Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.

    abstract:BACKGROUND:Patients with unresectable, metastatic colorectal cancer with wild type Kirsten ras mutational status are eligible for sequential treatments which include monoclonal antibodies as first line (1L), second line (2L), or third line (3L) regimens. OBJECTIVE:To compare the economic outcomes of different sequence...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.864973

    authors: Rautenberg T,Siebert U,Arnold D,Bennouna J,Kubicka S,Walzer S,Ngoh C

    更新日期:2014-02-01 00:00:00

  • Assessing the burden of nocturia in the workplace: the associations between nocturnal voiding, subjective well-being, work engagement and productivity.

    abstract::Aims: Nocturia (getting up at night to urinate, where each urination being followed by sleep or intention to sleep) is a bothersome symptom with potentially negative consequences for individual health and daytime functioning. This study assessed the burden of nocturia in the workplace by investigating associations bet...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1767631

    authors: Hafner M,Andersson FL,Burtea T,van Stolk C,Whitmore M,Yerushalmi E,Troxel WM

    更新日期:2020-09-01 00:00:00